Longeveron Inc.

LGVN Healthcare Biotechnology

Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.

1.39 0.11 −7.33%
Market cap
$4.8M
P/E
0.0×
Fwd P/E
−1.1×
Dividend yield
—
F-score
3/9
Altman Z
−24.10
Beneish M
−3.83
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 2 2
ROE
(119.93%) (164.75%) (135.18%) (203.61%)
ROA
(93.89%) (126.77%) (106.66%) (145.64%)
ROIC
(1,919.23%) (1,230.29%) (1,365.87%) (4,549.04%)
Return on Tangible Assets
(283.74%) (709.50%) (158.39%) (272.38%)
Average Days of Receivables
13.21 31.66 20.41 19.99
Free Cash Flow per Share
(9.46) (10.95) (7.49) (6.64)
Free Cash Flow
(17.38) (19.24) (18.56) (20.84)
Other line items

Show all line items

Columns are period end dates